Current and future perspectives on the TARGET system: the registration system for Glivec® established by the JSH
- 25 October 2008
- journal article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 88 (4), 409-417
- https://doi.org/10.1007/s12185-008-0186-0
Abstract
Since hematology is a highly specialized field, an individual physician may not have much direct treatment experience with a given disease. Therefore, the Japanese Society of Hematology (JSH) has discussed establishing a registry of hematologic disorders, in order to contribute to improving the quality of treatments and clinical outcomes in this field. As a first step, the Timely and Appropriate Registration System for GLIVEC Therapy (TARGET), a registration system for chronic myeloid leukemia (CML) patients treated with imatinib, was established in October 2003. We present the preliminary results of the first 4 years’ experience with this system. CML patients treated with imatinib in Japan were registered through the website and the patient’s clinical course, including parameters and events like imatinib dose, blood counts, adverse events, and efficacy were recorded in months 1, 3, 6, 9, and 12 and then every 6 months thereafter. By September 2007, 862 patients from 176 hospitals were registered. Follow-up period was 0–54 months, and 127 patients were followed-up for more than 36 months. Based on these cumulative data, present imatinib treatment trends were analyzed and safety and efficacy were compared with international trial data.Keywords
This publication has 11 references indexed in Scilit:
- Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisBlood, 2006
- New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib ResistanceAnnals of Internal Medicine, 2006
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2006
- Dasatinib (BMS-354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureBlood, 2006
- Cardiotoxicity of the cancer therapeutic agent imatinib mesylateNature Medicine, 2006
- Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive LeukemiasThe New England Journal of Medicine, 2006
- Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALLNew England Journal of Medicine, 2006
- Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2003
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeThe New England Journal of Medicine, 2001